Bevacizumab Biosimilar Mixture from Japan
Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Submit comparability protocols for biosimilars to FDA prior to import
• Ensure sterile filtration certification; test for endotoxins in bulk solutions
• Document mixture ratio to avoid disputes over 'unmixed' vs 'mixed' status